Iasocholine

Fluorocholine (18F) Chloride, the active ingredient in Iasocholine, is a radiopharmaceutical presented as a sterile injectable solution for intravenous use. It is employed in positron emission tomography (PET) imaging to highlight cells with increased phospholipid synthesis, aiding detection of certain cancers and hyperactive tissues. GNH USA supplies Iasocholine as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and imaging facilities worldwide.

Iasocholine, a fluorine‑18 labeled choline analogue, is used in PET imaging to assess metabolic activity in specific disease groups. - Prostate cancer: enhances visualization of malignant lesions for staging and recurrence assessment. - Brain tumors: highlights high‑grade gliomas and metastatic lesions to aid treatment planning. - Hyperparathyroidism: assists in localizing overactive parathyroid tissue prior to surgical intervention.

Adverse reactions to Iasocholine are generally mild, but clinicians should remain vigilant for any unexpected response.

Common Side Effects: - Nausea - Flushing - Mild headache - Injection site discomfort

Serious or Rare Side Effects: - Allergic reaction, including anaphylaxis - Severe hypotension - Radiation‑induced skin erythema

Prior to administration, appropriate safety and patient‑specific considerations are essential. - Assess renal function: evaluate creatinine clearance to ensure adequate tracer elimination. - Verify pregnancy status: avoid use in pregnant patients unless the diagnostic benefit outweighs risk. - Monitor vital signs: observe for immediate hypersensitivity or hemodynamic changes during and after injection. - Ensure proper hydration: adequate fluid intake facilitates tracer clearance and reduces radiation exposure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Fluorocholine may interact with substances that affect choline metabolism or PET imaging quality.

Major Interactions (Avoid): - High‑dose choline supplements: can competitively reduce tracer uptake. - Concurrent administration of other PET tracers with overlapping emission spectra: may interfere with image interpretation.

Moderate Interactions (Monitor Closely): - Anticholinergic medications: may alter biodistribution of the tracer. - Diuretics: can affect renal clearance and background activity. - Hyperglycemia: elevated glucose levels may compete with tracer uptake in certain tissues.